In the medical research field, the mission to cure cancer remains strong. One of the newer cancer treatments – immunotherapy – prompts the immune system to attack cancer cells. Pulitzer Prize–winning science journalist Matt Richtel elegantly writes about the state of immunotherapy cancer treatments as he balances scientific, technical aspects with personal stories of two cancer patients that keep the lay reader tuned into the medical issue and the question at the heart of the article: Are the risks of immunotherapy worth it? getAbstract recommends Richtel’s analysis to medical professionals and readers interested in medical breakthroughs.
In this summary, you will learn
- How immunotherapy harnesses patients’ immune systems to fight cancer,
- What risks the new treatment entails, and
- Why experts recommend more research into the treatment’s toxicology.
About the Author
New York Times reporter Matt Richtel received the Pulitzer Prize for National Reporting in 2010. He writes about science, technology and business and is the author of A Deadly Wandering and The Doomsday Equation.
Comment on this summary
Customers who read this summary also read
Vincent DeVita and Elizabeth DeVita-Raeburn
The New Yorker, 2015
The New Yorker, 2017